Presently, we are advancing our lead compound, GLIX1, in preclinical studies for the treatment of glioblastoma. Also, in the pipeline, at the proof of concept stage, is GLIX5, which is indicated in a much broader range of cancers. In addition, we have two compounds in late discovery stage. Further compounds are in the early stages of discovery.
